Showing 1251-1260 of 9359 results for "".
- Cutera, Inc. Appoints Jeff Jones as COOhttps://practicaldermatology.com/news/cutera-inc-appoints-jeff-jones-as-coo/2461956/Jeff Jones is Cutera, Inc.’s new Chief Operating Officer, effective August 28, 2023. Mr. Jones will report directly to Taylor Harris, Cutera’s Chief Executive Officer, and will be responsible for end-to-end operations, including manufacturing, quality, supply chain, field service engineering, and…
- One Year Data: Cutera’s AviClear Continues to Improve Acnehttps://practicaldermatology.com/news/one-year-data-cuteras-aviclear-comtinues-to-improves-acne/2461400/Cutera, Inc.’s AviClear improves acne in 92 percent of patients at one year, according to research presented at the Annual Fall Clinical Dermatology Conference in Las Vegas. Current clinical studies show that after three 30-minute treatment sessions, 90 percent of patients had a visible improvemen…
- LEO Pharma Taps Jörg Möller as EVP, Global Research and Developmenthttps://practicaldermatology.com/news/leo-pharma-taps-jorg-moller-as-evp-global-research-and-development/2460636/Jörg Möller is joining LEO Pharma A/S’s Global Leadership Team as Executive Vice President (EVP), Global Research and Development, effective January 1, 2021. Möller joins LEO Pharma from Bayer Pharma, where he has been EVP Head of R&D and Member of the Bayer Pharma Executive Committee. A medical …
- DermTech’s Pigmented Lesion Assay Receives Medicare Coveragehttps://practicaldermatology.com/news/dermtechs-pigmented-lesion-assay-receives-medicare-coverage/2460241/The Medicare Administrative Contractor Palmetto GBA MolDx issued a final local coverage determination for DermTech, Inc.'s Pigmented Lesion Assay (PLA). The PLA test is used to help rule out primary cutaneous melanoma and guide biopsy decisions of melanocytic skin lesions with one or more clinical …
- Newly Created Lancer Endowed Chair of Dermatology Honors Dr. Richard Rox Andersonhttps://practicaldermatology.com/news/newly-created-lancer-endowed-chair-of-dermatology-honors-dr-richard-rox-anderson/2460141/The inaugural Lancer Endowed Chair of Dermatology at Massachusetts General Hospital (MGH) is Richard Rox Anderson, MD, director of the MGH Wellman Center for Photomedicine. The Lancer Endowed Chair was announced on Sep. 4, 2019 by Harold Lancer, MD at the Paul S. Russell, MD Museum of Medical Hist…
- Allergan's CoolSculpting Treatment Now FDA Approved to Improve Appearance Of Lax Tissue in Double Chinhttps://practicaldermatology.com/news/allergans-coolsculpting-treatment-now-fda-approved-to-improve-appearance-of-lax-tissue-in-double-chin/2457956/The FDA has approved Allergan plc's CoolSculpting treatment for improved appearance of lax tissue in conjunction with submental fat, or double chin, treatments. CoolSculpting for the double chin is already clinically proven to reduce fat up to 20 percent in the treated area after one treatment. A…
- Lilly to Present New Data for Olumiant® and Taltz® at EADVhttps://practicaldermatology.com/news/lilly-to-present-new-data-for-olumiant-and-taltz-eadv/2458060/Eli Lilly and Company will present Phase 2 safety and efficacy data evaluating Olumiant® (baricitinib) for the treatment of moderate-to-severe atopic dermatitis (Lilly and Incyte Corporation are partners on the development of Olumiant) at the annual European Academy of Dermatology and Venereology C…
- Allergan and Paratek Pharmaceuticals' Acne Drug Performs Well in Phase 3 Trialshttps://practicaldermatology.com/news/allergan-and-paratek-pharmaceuticals-acne-drug-performs-well-in-phase-3-trials/2458234/Allergan and Paratek Pharmaceuticals, Inc.’s investigational acne drug performed well in two Phase 3 studies, the companies report. Sarecycline, a once-daily, oral, narrow spectrum tetracycline-derived antibiotic with anti-inflammatory properties for the potential treatment of moderate to severe a…
- FDA OKs Coolsculpting for Upper Arm Fat Reductionhttps://practicaldermatology.com/news/fda-oks-coolsculpting-for-upper-arm-fat-reduction/2458300/ZELTIQ® Aesthetics, Inc.’s CoolSculpting is now US Food and Drug Administration (FDA)-cleared for fat reduction in the upper arms. The company will be launching the CoolAdvantage Petite applicator to optimize the performance of CoolSculpting in the upper arms, with full commercial release targeted…
- Provectus Biopharmaceuticals Terminates CEO and COOhttps://practicaldermatology.com/news/provectus-biopharmaceuticals-terminates-ceo-and-coo/2458335/Provectus Biopharmaceuticals, Inc.'s Board of Directors unanimously voted to terminate Peter R. Culpepper, effective immediately, from all positions held with the company, including Chief Executive Officer and Chief Operating Officer, for cause in accordance with the terms of his employment agreeme…